Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

Unlocking the future of precision medicine:
The untapped power of RNA

True innovation in healthcare requires us to look beyond the obvious. For years, DNA sequencing has been the key pillar of precision medicine, offering insights into disease predispositions, mechanisms, and diagnosis that inform treatment.

May 23, 2025

Vol.51 No.20

By Eric Lefkofsky and Norman E. "Ned" Sharpless

Cancer Policy

Legislation to increase access to breast and cervical cancer screening introduced in the Senate

Legislation aimed at increasing access to breast and cervical cancer screening was introduced May 22 in the U.S. Senate. The bipartisan Screening for Communities to Receive Early and Equitable Needed Services, or SCREENS, for Cancer Act would reauthorize the National Breast and Cervical Cancer Early Detection Program, or NBCCEDP, for fiscal years 2026 through 2030.

May 23, 2025

Vol.51 No.20

Guest Editorial

An opportunity for Trump: Position U.S. cancer science to lead the world

Last November, the American public voted on America First causes, which include the greatest scientific discovery and achievement enterprise in the world: The National Institutes of Health. NIH has made America first in biomedical science for the past century.

Breast implant closes reconstruction gap for patients after mastectomy

Johnson & Johnson MedTech on May 13 announced the U.S. launch of MENTOR MemoryGel Enhance Breast Implants, filling a critical gap in comprehensive breast cancer care for women who have undergone a mastectomy.

May 16, 2025

Vol.51 No.19

Clinical Roundup

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Researchers at NCI have completed a comprehensive analysis of cancer statistics for different age groups in the United States and found that from 2010 through 2019, the incidence of 14 cancer types increased among people under age 50.

May 09, 2025

Vol.51 No.18

Clinical Roundup

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.

April 25, 2025

Vol.51 No.16

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

YOU MAY BE INTERESTED IN

Unlocking the future of precision medicine:
The untapped power of RNA

Legislation to increase access to breast and cervical cancer screening introduced in the Senate

An opportunity for Trump: Position U.S. cancer science to lead the world

Breast implant closes reconstruction gap for patients after mastectomy

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

YOU MAY BE INTERESTED IN

Unlocking the future of precision medicine:The untapped power of RNA

Legislation to increase access to breast and cervical cancer screening introduced in the Senate

An opportunity for Trump: Position U.S. cancer science to lead the world

Breast implant closes reconstruction gap for patients after mastectomy

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

Never miss an issue!

Login

Unlocking the future of precision medicine:
The untapped power of RNA